FMT

FMBL was found to be cost-effective compared to SOC for the prevention of rCDI with more benefits among patients at first recurrence, with an ICER far below the payer ICER threshold of $100,000. Patients treated with FMBL experienced higher total QALYs and reduced healthcare resource utilization, in …

FMBL has a cost-saving budget impact for a US payer, with higher initial drug costs being offset by savings in rCDI-related medical costs. Greater cost saving was found in patients at first recurrence.

Previous research has demonstrated that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) gains cell entry through the angiotensin-converting enzyme 2 receptor, which is abundantly found throughout the gastrointestinal (GI) tract, resulting in a wide array of GI manifestations of coro …

Fecal microbiota transplantation (FMT) is known to be highly effective in patients with recurrent Clostridioides difficile infection (rCDI), but its role in patients who also suffer from inflammatory bowel disease (IBD) is unclear. Therefore, we performed a systematic review and meta-analysis to eva …

Vowst represents the first oral live microbiota therapeutic approved for recurrent C. difficile infections.

“#Vowst capsules can be kept at room temp & taken by a patient at home. Dose is 4 capsules once a day for 3 consecutive days. In Phase 3 testing, Vowst showed a #Cdiff recurrence rate of 12.8% compared to a 39.8% rate in placebo group. Results in @NEJM: https://t.co/hMxJswSsJW”

The Europe Human Microbiome Market 2023 Report makes available the current and forthcoming technical and financial details of the industry It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies It ...

More than 40% of healthy mothers recruited for a study testing fecal transplantation for babies born by cesarean section tested positive for potentially harmful pathogens, Finnish researchers reported.

Treating Clostridioides difficile infection is complicated in patients coinfected with COVID-19. However, a new study suggests a significant benefit of fecal microbiota transplant (FMT) in these coinfected patients.

The treatment is the second live microbiota therapeutic approved by the FDA, coming just a few months after the agency approved RBX2660 for recurrent C. difficile infections.

Vowst (SER-109) has received FDA approval to treat recurrent C diff infection, making it the first oral microbiome therapeutic.

Researchers provide an overview of fecal microbiota transplantation in treating recurrent Clostridioides difficile infection.

The first-of-its-kind fecal microbiota pill treats recurrent infections caused by Clostridium difficile, an antibiotic-resistant bacterium that's a danger to nursing home residents.

Fecal microbiota transplantation (FMT) can induce clinical remission in ulcerative colitis (UC) patients. Enemas, nasoduodenal tubes, and colonoscopies are the most common routes for FMT administration. However, there is a lack of definitive evidence regarding the effectiveness of capsulized FMT tre …

Regulators clear capsules for adults who face risks from C diff, bacteria that can cause nausea, cramps and diarrhea

More than a year after imposing a clinical hold on MaaT Pharma’s lead microbiome therapeutic in 2021, the US Food and Drug Administration (FDA) has given clearance for the French firm to begin a phase 3 trial in the US.

Dr Paul Feuerstadt joins Dr David Hudesmand and Dr Jordan Axelrad in a discussion about treatment approaches for C difficile infections, and the latest advances in treating recurrent infections with fecal microbiota transplantation.

FDA approves first orally administered fecal microbiota product for prevention of recurrence of Clostridioides difficile infection in adults

The FDA approved a new drug from Seres Therapeutics that uses bacteria to treat a bowel disorder, making it the second microbiome therapy to hit the market.

Vedanta Biosciences, which is developing a potential new category of oral therapies based on defined bacterial consortia, has raised $106.5M.

Vowst, the first-ever oral fecal microbiome-based therapeutic, is indicated for preventing C. diff recurrence in adults following antibacterial treatment.

Regulators clear capsules for adults who face risks from C diff, bacteria that can cause nausea, cramps and diarrhea

Fecal microbiota transplantation may result in a slight reduction in serious adverse events, but the confidence intervals around the summary estimate were wide in immunocompetent adults with recurrent C. difficile infection.

Vowst represents the first oral live microbiota therapeutic approved for recurrent C. difficile infections.

Vowst is expected to be available in June 2023.

Recurrent Clostridioides difficile infection can be treated with fecal microbiota transplants. FDA approval of Seres Therapeutics’ Vowst makes it the first oral microbiome therapy.

The-FDA-approved-the-first-fecal-microbiota-product-that-is-taken-orally-to-prevent-recurrent-CDI-in-people-who-are-18-years-of-age-and-older-following

Vowst photo pending KEY POINTS Fecal microbiota spores, live-brpk goes by brand name Vowst and was studied as SER-109 Is a product of Seres Therapeutics Manufactured from human fecal matter sourced from donors The spore suspension is generated by treating fecal matter with ethanol to kill organisms that are not spores, which is followed by …